🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

US STOCKS-U.S. stocks close down on news of Biden tax proposal

Published 22/04/2021, 21:29
© Reuters.
US500
-
DJI
-
MSFT
-
GOOGL
-
AAPL
-
AMZN
-
BIIB
-
TSLA
-
IXIC
-
META
-
AAL
-
GOOG
-
SPXHC
-
SPLRCI
-

* AT&T rises on strong quarterly results
* U.S. weekly jobless claims decline further
* Indexes down: Dow 0.94%, S&P 500 0.92%, Nasdaq 0.94%

(Adds prices after 4 p.m. market close)
By Herbert Lash
NEW YORK, April 22 (Reuters) - U.S. stocks dived on Thursday
on reports President Joe Biden planned to almost double the
capital gains tax, news analysts said provided an excuse to take
profits in a directionless market ahead of big tech's earnings
next week.
The three main indexes on Wall Street also fell on reports
that Biden planned to raise income taxes on the wealthy, a
proposal some said would be hard to pass in Congress.
"If it had a chance of passing, we'd be down 2,000 points,"
said Thomas Hayes, chairman and managing member at hedge fund
Great Hill Capital LLC.
Paul Nolte, portfolio manager at Kingsview Investment
Management in Chicago, said when a proposal is floated about
raising taxes or capital gains, everybody gets excited, sells
first and asks questions later.
"It is more of a short-term, knee-jerk reaction," he said.
Biden will propose raising the marginal income tax rate to
39.6% from 37% and nearly double capital gains taxes to 39.6%
for people earning more than $1 million, sources told Reuters.
The proposal targets about $1 trillion for child care,
universal pre-kindergarten education and paid leave for workers,
the sources said.
Markets have been listless after the Dow .DJI and S&P 500
.SPX recently scaled all-time peaks as investors await
guidance from Microsoft Corp MSFT.O , Google parent Alphabet
Inc GOOGL.O and Facebook Inc FB.O when they report earnings
next week.
"Until we get out of this information vacuum the market is
going to be generally directionless," he said. "All that really
matters moving forward is what are those big tech earnings next
week?"
During the session, the S&P 500 healthcare sector .SPXHC
hit a fresh record high while industrials .SPLRCI were the
biggest gainers.
American Airlines Group Inc AAL.O and Southwest Airlines
Co LUV.N reported smaller-than-expected quarterly losses,
signaling a revival in travel demand. Both stocks fell, with
American down 4.5% and Southwest 1.6%. Investors welcomed data showing the number of Americans
filing new claims for unemployment benefits last week dropped to
a fresh one-year low. The Labor Department report suggested
layoffs were subsiding and expectations were rising for another
month of blockbuster job growth in April. The speedy U.S. vaccination rollout has improved the
economic outlook as people plan summer vacations and leisure
spending, but a surge in COVID-19 cases in India and elsewhere
in Asia has kept investors anxious, Hayes said.
Equities have likely reached a near-term top as expectations
are too high, said Randy Frederick, vice president of trading
and derivatives at Charles Schwab.
"There's going to be continued positive moves throughout the
remainder of the year but we are due for some sort of a pullback
in the very short term," he said. "Then the dip buyers will step
back in."
First-quarter earnings are expected to increase 31.9% from a
year ago, the highest rate since the fourth quarter, according
to IBES Refinitiv data.
All 11 S&P 500 sectors closed lower as Microsoft, Apple Inc
AAPL.O , Amazon.com Inc AMZN.O and Tesla Inc TSLA.O
weighted the most on the downdraft.
The Dow Jones Industrial Average .DJI fell 0.94% to
33,815.9, the S&P 500 .SPX lost 0.92% at 4,134.98, and the
Nasdaq Composite .IXIC dropped 0.94% to 13,818.41.
Volume on U.S. exchanges was 10.35 billion shares, compared
with the 10.32 billion full-session average over the last 20
trading days.
AT&T Inc T.N beat Wall Street revenue targets as the U.S.
economic reopening following pandemic-linked restrictions
boosted smartphone sales and the media business. AT&T shares
rose 4.2%.
Biogen Inc BIIB.O beat quarterly profit estimates on
stronger-than-expected sales for its muscle wasting disorder
drug, though concerns over its reliance on its yet-to-be
approved Alzheimer's therapy, aducanumab, weighed on shares.
Biogen shares fell 4.0%.
Declining issues outnumbered advancing ones on the NYSE by a
1.57-to-1 ratio; on Nasdaq, a 1.04-to-1 ratio favored decliners.
The S&P 500 posted 84 new 52-week highs and no new lows; the
Nasdaq Composite recorded 86 new highs and 20 new lows.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.